Tevogen Bio (NASDAQ:TVGN) Shares Up 4.5%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN)’s stock price shot up 4.5% during mid-day trading on Friday . The company traded as high as $0.46 and last traded at $0.46. 372,213 shares were traded during mid-day trading, a decline of 24% from the average session volume of 488,400 shares. The stock had previously closed at $0.44.

Wall Street Analyst Weigh In

Separately, Fundamental Research set a $4.20 target price on Tevogen Bio and gave the stock a “buy” rating in a research note on Friday, June 28th.

Tevogen Bio Price Performance

The company has a 50-day simple moving average of $0.58 and a 200 day simple moving average of $1.55.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio accounts for approximately 3.0% of Portland Global Advisors LLC’s holdings, making the stock its 9th biggest position. Portland Global Advisors LLC owned approximately 36.55% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.